News

Sermonix Pharmaceuticals Announces Recent Closure of $4.2 Million Seed Preferred Equity Bridge to Fund Operations, Prepare for Phase II Breast Cancer Study

Biotechnology company will globally develop and commercialize drug for treatment of advanced metastatic breast cancer. COLUMBUS, OH–(Marketwired – Oct 31, 2017) – Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced its recent completion of a $4.2 million [...]
Read more

Sermonix Pharmaceuticals Secures Worldwide Rights to Oral Lasofoxifene From Ligand Pharmaceuticals, Expanding From U.S., Japan

Accord allows Sermonix to globally develop and commercialize drug for treatment of advanced breast cancer COLUMBUS, OH–(Marketwired – Feb 28, 2017) – Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced it licensed worldwide rights to develop and [...]
Read more

Sermonix Pharmaceuticals Signs Exclusive Licensing Agreement to Further Explore Lasofoxifene For Breast Cancer Treatment

Women’s Oncology Pharmaceutical Company Also Raises More Than $2 Million in Preferred Seed Funding Round  COLUMBUS, OH, (December 7, 2016) – Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced that it signed a licensing agreement through which Sermonix will gain exclusive [...]
Read more

Sermonix Pharmaceuticals to Present Poster on Physician Perceptions of Menopausal Serms at San Antonio Breast Cancer Symposium

 COLUMBUS, OH (November 28, 2016) – Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that its poster on physician perceptions of estrogen agonist/antagonists in menopausal health has been accepted for presentation at the San Antonio Breast Cancer Symposium (SABC). The Dec. [...]
Read more

Sermonix Pharmaceuticals’ Exploratory Analysis on Orgasm Frequency With SERMs Is Named Featured Poster for 2016 North American Menopause Society Annual Meeting

Sermonix Also to Present Poster on Physicians’ Perceptions of SERMs in Menopausal Health COLUMBUS, OH–(Marketwired – Sep 26, 2016) – Sermonix Pharmaceuticals Inc., a specialty pharmaceutical company focused on late-stage women’s health products, today announced that its exploratory analysis on sexual activity and orgasm frequency in menopause will be one of three [...]
Read more

Sermonix Pharmaceuticals Convenes Breast Cancer Oncology Steering Committee to Explore Utility of Lasofoxifene

COLUMBUS, OH–(Marketwired – Aug 3, 2016) – Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on late-stage women’s health products, convened the inaugural meeting of its Oncology Steering Committee July 14th in New York City. The group, which included world-renowned experts focused on the prevention, diagnosis and treatment of breast cancer, [...]
Read more

NY Times Opinion Pages: Women’s Wariness of the Risks of Osteoporosis Drugs

  From the June 15th, 2016 New York Times: As a practicing obstetrician-gynecologist for 20 years, I saw firsthand how fear could be a very real factor in patient decision-making. Bisphosphonates are drugs that reduce osteoporotic fractures by suppressing bone turnover at a higher rate than normal. In rare cases, overpowering this natural remodeling process […]
Read more

Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild As Board Chairman and Investor

Investment and New Board Leadership Will Support the Path to Commercialization for Investigational Drug, Lasofoxifene  COLUMBUS, OH (May 3, 2016) – Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, today announced Anthony H. Wild, Ph.D., as Chairman of the Board and also a [...]
Read more

Sermonix Pharmaceuticals to Give Lasofoxifene Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Disease

COLUMBUS, OH (March 31, 2016) – Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, announced today it will deliver an oral presentation related to its investigational drug, lasofoxifene, at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Disease (WCO-IOF-ESCEO) [...]
Read more

Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International Society for the Study of Women’s Sexual Health Meeting

Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, announced today that experts in sexual medicine will give two presentations related to its investigational drug, lasofoxifene, at the annual meeting of the International Society for the Study of Women’s Sexual Health (ISSWSH) on [...]
Read more